IntoCell and Xcellon Biologics partner to expand access to next-generation ADC technologies

CAR-T Digest - August 2020

31 October 2025: IntoCell and Xcellon Biologics partner to expand access to next-generation ADC technologies

Xcellon Biologics, a leading ADC-focused CDMO, has entered into a partnership with IntoCell Inc. to expand global access to next-generation ADC linker-payload technologies
The collaboration integrates IntoCell’s proprietary OHPAS platform, which includes duocarmycin and nexatecan payloads, with Xcellon’s expertise in ADC process development, bioconjugation, analytical methods, and scalable manufacturing
This strategic alliance enables biotech and pharma innovators to accelerate early-stage ADC pipelines by leveraging advanced chemistry and flexible production capabilities
Both companies aim to bridge the gap between discovery and manufacturability, combining IntoCell’s discovery-driven linker-payload systems with Xcellon’s U.S.-based end-to-end CDMO infrastructure
The partnership strengthens Xcellon’s global ADC development network, fostering innovation and efficiency in the creation of differentiated antibody-drug conjugates for oncology and beyond